ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glomerulonephritis, IGA
Conditions
Glomerulonephritis, IGA, Nephropathy, IGA, IGA Nephropathy
Trial Timeline
Jan 1, 2006 → Feb 1, 2010
NCT ID
NCT00396721About ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin
ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin is a phase 2 stage product being developed by Pfizer for Glomerulonephritis, IGA. The current trial status is completed. This product is registered under clinical trial identifier NCT00396721. Target conditions include Glomerulonephritis, IGA, Nephropathy, IGA, IGA Nephropathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00396721 | Phase 2 | Completed |
Competing Products
8 competing products in Glomerulonephritis, IGA
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil | Daiichi Sankyo | Phase 2 | 52 |
| infusion of ADR-001 (Mesenchymal stem cell) | Rohto Pharmaceutical | Phase 1 | 33 |
| Iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Roche | Phase 2/3 | 65 |
| Ramipril | Sanofi | Phase 3 | 76 |
| MOR202 | Biogen | Phase 1/2 | 38 |
| MOR202 | Biogen | Phase 2 | 49 |